FDA approves Afrezza for pediatric diabetes patients ages 6+

MANNKIND CORP

FDA approved supplemental BLA for Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.
More than 350,000 U.S. children and adolescents live with diabetes; majority have type 1 and require lifelong insulin.
Approval fulfills the last postmarketing requirement from the original June 27, 2014 approval letter.
MannKind expects to expand the patient population for Afrezza beyond adults.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.